CD53 and breast carcinoma: Regarding breast cancers, while the survival outcome of hormone receptor- or HER2-positive BC has been improved by the development of HER2-targeting mAbs or antibody–drug conjugates, the lack of targetable cell surface antigen has deeply hampered the development of anti-tumor antibody-based therapies for TNBC.